IST
SOFHOUR Finance SOFHOUR Finance
IPO desk
Sign in
Report a bugTell us what went wrong. We read every report.

What kind of problem?

We also send the page link and your browser name, to help us fix it.

Healthcare · NIFTY 500

Dr. Lal Path Labs Limited

NSELALPATHLAB BSE539524 ISININE600L01024 SeriesEQ Listed on NSE · BSE

₹2,016.00 -12.70 (-0.63%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener
Price, daily close+24.90% in a year

Today

Open
₹2,028.70
Prev close
₹2,028.70
Day high
₹2,049.00
Day low
₹1,998.10
Volume
2.34 L
Value traded
₹47.30 Cr
Upper circuit
₹2,434.40
Lower circuit
₹1,623.00
52W high
₹2,061.90
52W low
₹1,272.60
1 month
+3.72%
6 months
+19.19%
52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹33,828 Cr
P/E (TTM)57.83
P/B12.33
Book value / share₹163.56
EPS (TTM)₹34.86
ROE21.3%
Dividend yield0.87%
Dividend (12m)₹17.50 / share
Net margin (TTM)19.2%
Operating margin32.1%
Debt / equity—
Current ratio3.86
EV / EBITDA38.77
Sales growth (YoY qtr)+19.61%
Profit growth (YoY qtr)+27.62%
Sales CAGR 3Y+11.06%
Profit CAGR 3Y+28.32%
Shares16.78 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

53981.3
Dec 23
54584.5
Mar 24
602106
Jun 24
660129
Sep 24
59796.7
Dec 24
603155
Mar 25
670132
Jun 25
731151
Sep 25
66090.5
Dec 25
703131
Mar 26
798170
Jun 26
874192
Sep 26

Revenue · QoQ (vs last quarter)

—+1.2%+10%+9.7%-9.6%+1.0%+11%+9.1%-9.7%+6.5%+14%+9.6%

Revenue · YoY (vs a year ago)

————+11%+10%+11%+11%+11%+17%+19%+20%

Net profit · QoQ (vs last quarter)

—+3.9%+26%+21%-25%+60%-14%+14%-40%+45%+29%+13%

Net profit · YoY (vs a year ago)

————+19%+83%+24%+17%-6.4%-15%+28%+28%
RevenueNet profitLine = trend
9.76
Dec 23
10.12
Mar 24
12.76
Jun 24
15.48
Sep 24
11.58
Dec 24
18.54
Mar 25
15.85
Jun 25
18.01
Sep 25
5.41
Dec 25
7.85
Mar 26
10.13
Jun 26
11.47
Sep 26

EPS (₹) · YoY (vs a year ago)

————+19%+83%+24%+16%-53%-58%-36%-36%
EPS (₹)Line = trend

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

1,203294199
FY19
1,330344226
FY20
1,581436292
FY21
2,087561345
FY22
2,017490239
FY23
2,227609358
FY24
2,461696487
FY25
2,763752505
FY26

Revenue · YoY (vs a year ago)

—+11%+19%+32%-3.4%+10%+11%+12%

Net profit · YoY (vs a year ago)

—+13%+29%+18%-31%+50%+36%+3.6%
RevenueOperating profitNet profitLine = trend

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

1,666237264
Mar 23
1,84983.3361
Mar 24
2,173293
Mar 25
2,508243
Mar 26
2,745344
Sep 26

Shareholders' equity · YoY (vs a year ago)

—+11%+17%+15%—
Shareholders' equityBorrowingsCashLine = trend

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

447-449136
FY22
456-287-283
FY23
535-24.3-414
FY24
569-303-334
FY25
636-422-264
FY26

Operations · YoY (vs a year ago)

—+2.1%+17%+6.2%+12%
OperationsInvestingFinancingLine = trend

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

54.6%Mar 24
54.6%Jun 24
53.9%Sep 24
53.9%Dec 24
53.9%Mar 25
53.8%Jun 25
53.2%Sep 25
53.2%Dec 25
53.2%Dec 25
53.2%Mar 26
53.2%Jun 26
52.9%Sep 26
Promoter & groupPublic

Latest (30 Sep 2026)

52.9%promoter
Promoter & group
52.93%
Public (FIIs, mutual funds, retail…)
46.66%
Employee trusts
0.41%
Promoter change, last quarter
-0.26 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

  • Interim Dividend - Rs 5 Per Share
  • Interim Dividend - Rs 5 Per Share
  • Dividend - Rs 4 Per Share
  • Interim Dividend - Rs 3.50 Per Share
  • Bonus 1:1
  • Interim Dividend - Rs 7 Per Share
  • Interim Dividend - Rs 6 Per Share
  • Dividend - Rs 6 Per Share

Board meetings

  • Dividend.
  • 2nd interim dividend for FY 26-27, if any
  • the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
  • the financial results for the period ended September 30, 2026 and other business matters
  • Dividend.

Filings with NSE

  • Shareholders meeting
  • Analysts/Institutional Investor Meet/Con. Call Updates
  • Analysts/Institutional Investor Meet/Con. Call Updates
  • Copy of Newspaper Publication
  • Analysts/Institutional Investor Meet/Con. Call Updates
  • Press Release
  • Investor Presentation

About

About Dr. Lal Path Labs Limited

Dr Lal PathLabs Limited is an Indian service provider of diagnostic and related healthcare tests. Based in New Delhi, the company offers tests on blood, urine and other human body viscera.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name
Dr. Lal Path Labs Limited
NSE symbol
LALPATHLAB
BSE scrip code
539524
ISIN
INE600L01024
Listed on
NSE, BSE
Series
EQ (normal equity)
Listed on NSE since
23 Dec 2015
Face value
₹10 per share
Market lot
1 share
Shares issued
16.78 crore
Index
NIFTY 500
Sector (NSE)
Healthcare
Industry
Medical/Nursing Services
Managing director / CEO
Shankha Banerjee
Chair
Arvind Lal
Headquarters
Gurugram, Haryana, India
Registered address
12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122001
Founded
1949
Employees
6,200
Financial year
April to March
Results basis
Consolidated

Peers

Other Healthcare stocks

  1. DIVISLABDivi's Laboratories ₹11,485.00 +1.04%
  2. ALKEMAlkem Laboratories ₹5,302.00 -2.68%
  3. GRANULESGranules India ₹840.50 +5.16%
  4. SUNPHARMASun Pharmaceutical Industries ₹1,885.00 -0.91%
  5. LAURUSLABSLaurus Labs ₹2,400.00 -1.19%
  6. AUROPHARMAAurobindo Pharma ₹1,807.20 -1.11%
  7. ACUTAASAcutaas Chemicals ₹3,996.10 +2.02%
  8. APOLLOHOSPApollo Hospitals Enterprise ₹8,515.00 -1.03%

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.